Eloralintide (LY3841136)

Eloralintide (LY3841136) is an investigational once-weekly injectable peptide from Eli Lilly that selectively activates the amylin 1 receptor, studied for obesity.

It activates the amylin 1 receptor, which promotes satiety. In cell assays it was about 12-fold more active there than at the calcitonin receptor and 11-fold more than at the amylin 3 receptor.

No. Eloralintide is investigational and not approved anywhere. Phase 3 trials started in 2026.

Phase 2 (Lancet 2025): 263 adults with obesity for 48 weeks; mean weight change from −9% to −20% across dose groups vs −0.4% with placebo. Phase 3 trials started in 2026.

In phase 2 the most common adverse events were nausea (11–64% across eloralintide groups vs 14% with placebo) and fatigue (0–46% vs 12%). In phase 1, most adverse events were mild.

Phase 3 efficacy and safety, long-term effects and cardiovascular outcomes are not known yet; the phase 2 trial included 263 people for 48 weeks.

No dose is approved. The trial dose groups are part of each trial's design and are described in the linked publications; they are not a recommendation.

There is no approved product label, so no official storage instructions exist outside the clinical trials, where the sponsor supplies the investigational product and its storage conditions.

It is not named individually on the 2026 WADA Prohibited List. Under section S0 (non-approved substances), any pharmacological substance without a current approval by a government health authority for human therapeutic use is prohibited at all times, so the investigational compound falls under S0 until it is approved. Athletes should confirm with their national anti-doping organisation.

Egypt Peptides publishes reviewed scientific reference monographs for documentation and research. The site does not give individual medical advice, preparation or injection instructions, combination protocols or off-label use instructions. Decisions about any medicine belong to the treating physician.